Abiraterone Acetate in Combination With Tildrakizumab

Metastatic Castration Resistant Prostate Cancer Clinical Trial

— ACTIon  

Official title:

ACTION: Phase I/II Trial of Abiraterone Acetate in Combination With Tildrakizumab (Anti-IL23 Targeting Monoclonal Antibody) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04458311
• Other study ID #: CCR5163
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: December 1, 2020
• Est. completion date: November 15, 2023

Study information

• Verified date: April 2024
• Source: Institute of Cancer Research, United Kingdom
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out the side effects and safety of a combination of the anti-IL23 targeting monoclonal antibody tildrakizumab in combination with abiraterone acetate in men with metastatic castration resistant prostate cancer and to determine the most appropriate dose of this combination. In the Phase I part of this study small groups of patients will be treated with increasing doses of tildrakizumab in combination with a fixed dose of abiraterone acetate (500mg once daily). Once Phase I has been completed the combination with the optimum safety and pharmacokinetic/pharmacodynamic profile will be taken forward to the Phase II part of the study. The Phase II part of the study will evaluate the optimized dose/schedule identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.

Description:

The trial will be divided into 2 parts: Phase I and Phase II.

The Phase I study will adopt a Bayesian Continual Reassessment Method. Patients will receive single-agent abiraterone run-in of 500 mg orally, once daily (continuous dosing) along with prednisolone at 5 mg BD until PSA progression on abiraterone monotherapy is confirmed. This run-in will not be required if patients have been treated with abiraterone in the previous 6 months. Upon confirmation of PSA progression, tildrakizumab IV will be started and given once every 4-weeks in combination with the fixed dose abiraterone (and prednisolone). The starting dose of tildrakizumab will be 100mg, with single dose escalations to 300mg and 600mg to determine the RP2D to take forward to the Phase II study. Depending on the number of responses observed, dose levels that are deemed tolerable may be expanded to up to a total of 10 patients who are evaluable for response.

The Phase II study will employ a two-stage Minimax design, recruiting up to 25 patients. During the first stage, 15 evaluable patients will be enrolled and followed for a minimum of 2 cycles each. If there are one or more responses confirmed at least 4-weeks later, an additional 10 evaluable patients will be recruited. If 4 or more responses are seen in the 25 patients evaluable for response, the combination will be deemed successful, warranting further evaluation in subsequent phases of testing. In the phase II study, patients will start taking 500mg abiraterone as an oral tablet once daily along with 5mg of prednisolone twice daily until PSA progression on abiraterone monotherapy is confirmed. This run-in will not be required if patients have been treated with abiraterone in the previous 6 months. Upon confirmation of PSA progression, the tildrakizumab will be given as an intravenous infusion at the dose established in the Phase I safety part of the study in combination with the abiraterone (and prednisolone) from combination Cycle 1 Day 1 onwards.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 13
• Est. completion date: November 15, 2023
• Est. primary completion date: April 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up.

2. Age 18 or above.

3. Histologically or cytologically proven adenocarcinoma of the prostate.

4. Metastatic castration resistant prostate cancer

5. Documented prostate cancer progression as assessed by the investigator with RECIST (v1.1) and PCWG3 criteria with at least one of the following criteria:

1. Progression of soft tissue/visceral disease by RECIST (v1.1) and/or,

2. Progression of bone disease by PCWG3 bone scan criteria and/or,

3. Progression of PSA by PCWG3 PSA criteria and/or,

4. Clinical progression with worsening pain and need for palliative radiotherapy for bone metastases.

6. Patients that have progressed after either enzalutamide or abiraterone treatment (having received a minimum of 12-weeks of enzalutamide or abiraterone).

7. Ongoing androgen deprivation with a luteinizing hormone releasing hormone analogue (unless the patient is surgically castrated) maintaining serum testosterone of less than 50 ng/dL (less than 2.0 nM) is mandatory.

8. Life expectancy of at least 12-weeks.

9. World Health Organisation (WHO) performance status of 0-2

10. Able to swallow the study drug.

11. Archival tissue must be available for research analysis.

12. Patients must have disease that is amenable to biopsy and must be willing to undergo tumour biopsies.

13. Haematological and biochemical indices within the required ranges in protocol. These measurements must be performed within two weeks prior to the patient's first dose of any investigational medicinal products (IMP).

Exclusion Criteria:

1. Patients with predominantly small cell or neuroendocrine differentiated prostate cancer are not eligible.

2. Prior therapy, including major surgery, chemotherapy, radium-223, or other anti-cancer therapy within 4-weeks prior to IMP administration. Patients who were receiving abiraterone acetate (Zytiga® or Yonsa™) immediately prior to trial entry will not need to undergo a washout period. The use of bisphosphonates or RANK ligand inhibitors, provided the patient has been on a stable dose without any dose adjustment for at least 30 days prior to combination Cycle 1 Day 1, in patients with known osteopenia or osteoporosis or bone metastases is permitted. A single fraction of palliative radiation is permitted if at least 14-days before starting trial treatment.

3. Prior hormonal treatment exclusions as follows:

• prior flutamide treatment during previous four-weeks N.B. Patients whose PSA did not decline in response to antiandrogens given as a second line or later intervention will only require a 14-day washout;

• prior bicalutamide (Casodex) and nilutimide (Nilandron) treatment during previous six-weeks;

• prior progesterone, medroxyprogesterone, progestins, cyproterone acetate, tamoxifen, and 5-alpha reductase inhibitors during previous two-weeks (14-days).

4. Live vaccine within 4 weeks of starting trial treatment and up to 17 weeks from the last dose of Tildrakizumab.

5. Prior limited field radiotherapy within the previous two weeks (14-days), or wide field radiotherapy within the previous four weeks of trial entry.

6. Participation in another interventional clinical trial and any concurrent treatment with any investigational drug within four weeks prior to IMP administration.

7. Any toxicities due to prior chemotherapy and/or radiotherapy that have not resolved to NCI-CTCAE v5.0 Grade =1 with the exception of chemotherapy induced alopecia and Grade 2 peripheral neuropathy.

8. Clinical evidence of hyperaldosteronism or hypopituitarism.

9. Use of drugs that are known strong CYP3A4 inducers and CYP2D6 substrates with a narrow therapeutic index (please refer to http://medicine.iupui.edu/clinpharm/ddis/table.aspx). Seville orange or grapefruit products, and any herbal medications should be avoided for four weeks prior to starting trial treatment.

10. Malabsorption syndrome or other condition that would interfere with enteral absorption of the study drugs.

11. Known intracerebral metastases

12. Any of the following cardiac criteria:

1. QT interval > 470 msec.

2. Clinically important abnormalities including rhythm, conduction or ECG changes (left bundle branch block, third degree heart block).

3. Factors predisposing to QT prolongation including congenital long QT syndrome; family history of prolonged QT syndrome, unexplained sudden death (under 40); concomitant medications known to prolong QT interval.

4. Coronary artery bypass, angioplasty, vascular stent, myocardial infarction, angina or congestive heart failure (NYHA = grade 2) in the last 6 months (see the NYHA scale).

13. Uncontrolled hypotension (systolic blood pressure < 90mmHg and or diastolic blood pressure < 50 mmHg).

14. Uncontrolled hypertension on optimal medication (systolic blood pressure >180, diastolic blood pressure > 100).

15. Patients with known history of adrenal insufficiency or mineralocorticoid excess.

16. Patients with a significant history of liver disease (Child-Pugh B or C, viral or other hepatitis, current alcohol abuse or cirrhosis).

17. Known history of hepatitis B, hepatitis C or human immunodeficiency virus (HIV).

18. At high medical risk because of non-malignant systemic disease including active infection, latent or active TB.

19. Known history of tuberculosis.

20. Poorly controlled diabetes with HbA1C > 7.5%.

21. Malignancy other than prostate cancer within three-years of trial entry with the exception of adequately treated basal cell carcinoma. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy must have no evidence of that disease for at least-three years and be deemed at negligible risk for recurrence, are deemed eligible.

22. Immunocompromised patients including patients who have previously received organ transplants or are on long-term immunosuppression (e.g. corticosteroids of > 10 mg daily equivalent of prednisolone).

23. Active or uncontrolled autoimmune disease requiring corticosteroid therapy or other forms of systemic immunosuppression.

24. Any other finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect interpretation of the results or renders the patients at high risk from treatment complications e.g. patients with a hypersensitivity to tildrakizumab, abiraterone, prednisolone, or any of the drug excipients.

25. Patients with female partners of child-bearing potential (unless they agree to take measures not to father children by using a barrier method of contraception [condom plus spermicide] or to sexual abstinence effective from the first administration of any of the study drugs throughout the trial and for six months afterwards. Men with partners of child-bearing potential must also be willing to ensure that their partner uses an effective method of contraception for the same duration for example, hormonal contraception, intrauterine device, diaphragm with spermicidal gel or sexual abstinence). Men with pregnant or lactating partners must be advised to use barrier method contraception (for example, condom plus spermicidal gel) to prevent exposure of the foetus or neonate.

NB. Abstinence is only considered to be an acceptable method of contraception when this is in line with the preferred and usual lifestyle of the participants. Periodic abstinence (e.g., calendar, ovulation, sympathothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception

26. Prior bone marrow transplant.

27. Extensive radiotherapy to greater than 25% of bone marrow within 8 weeks.

28. Any other condition, which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.

29. Symptoms of COVID-19 and/or documented COVID-19 infection

Related Conditions & MeSH terms

• Metastatic Castration Resistant Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Abiraterone Acetate
Supplied as 125 mg tablets
• Tildrakizumab
Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.

Locations

Country	Name	City	State
Switzerland	Bellinzona Hospital	Bellinzona
United Kingdom	Belfast City Hospital	Belfast	UK
United Kingdom	Addenbrooke's Hospital	Cambridge
United Kingdom	Cancer Research Centre at Weston Park Hospital	Sheffield	England
United Kingdom	University Hospitals Southampton NHS Foundation Trust	Southampton
United Kingdom	The Royal Marsden Hospital Foundation Trust	Sutton	UK

Sponsors (2)

Lead Sponsor	Collaborator
Institute of Cancer Research, United Kingdom	Sun Pharmaceutical Industries Limited

Countries where clinical trial is conducted

Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To determine mechanisms of resistance to the combination of tildrakizumab and abiraterone.	Deregulation, amongst others, of IL-23, STAT proteins, AR, AR splice variants.	32 months
Other	To assess putative predictive biomarkers of response to this combination.	Correlate anti-tumour activity of the combination of tildrakizumab and abiraterone with the detection of putative predictive biomarkers of response and resistance in archival tumours, paired fresh tumour biopsies, and plasma samples.	32 months
Primary	Phase I - To describe the safety and tolerability of abiraterone acetate and tildrakizumab when given in combination. To establish a RP2D for tildrakizumab, in combination with abiraterone.	To determine a maximum tolerated dose (MTD) of tildrakizumab by establishing the dose at which the DLT rate is as close to the target DLT rate of 15% as possible, in combination with abiraterone at 500 mg OD with prednisolone at 5 mg bid, and is deemed to be tolerable by the Safety Review Committee. This will be the RP2D for tildrakizumab.	20 months
Primary	Phase II - To determine the antitumour activity of tildrakizumab (at RP2D) in combination with abiraterone in men with mCRPC.	Antitumour activity will be defined by response rate on the basis of the following outcomes. If any of the following occur, patients will be considered to have responded: PSA decline = 50% criteria confirmed 4-weeks or later and/or,; Confirmed soft tissue objective response by RECIST (v1.1) in patients with measurable disease and/or,; ONLY for patients with detectable circulating tumour cell (CTC) count of = 5/7.5ml blood at baseline, conversion of CTC count to <5/7.5ml blood nadir.	12 months
Secondary	Phase I - To investigate the PD effects of the tildrakizumab and abiraterone combination in men with mCRPC.	Measuring the impact of the downregulation of IL-23 signaling in tumour, also evaluating the downregulation of androgen receptor (AR), AR splice variants, and AR target genes.	20 months
Secondary	Phase I - To characterize the PK profile of the tildrakizumab and abiraterone combination in men with mCRPC - CMax.	Determine peak plasma concentration (Cmax) of tildrakizumab and abiraterone when dosed together.	20 months
Secondary	Phase I - To characterize the PK profile of the tildrakizumab and abiraterone combination in men with mCRPC - T1/2.	Determine the terminal elimination half-life (T1/2) of tildrakizumab and abiraterone when dosed together.	20 months
Secondary	Phase I - To characterize the PK profile of the tildrakizumab and abiraterone combination in men with mCRPC - AUC	Determine the area under the plasma concentration versus time curve (AUC) of tildrakizumab and abiraterone when dosed together.	20 months
Secondary	Phase I - To identify molecular determinants of response and anti-tumour activity of the combination of tildrakizumab and abiraterone in men with mCRPC.	Determine biomarkers of response, including but not limited to PTEN loss, MYC amplification, and intra-tumour MDSC counts, in tumour biopsies from responders and non-responders.	20 months
Secondary	Phase I - To determine preliminary anti-tumour activity of the tildrakizumab and abiraterone combination in men with mCRPC.	Response and progression will be determined using the same measures as that described for the primary objective of the Phase II study.	20 months
Secondary	Phase I - To evaluate progression-free survival (PFS) in mCRPC patients receiving the tildrakizumab and abiraterone combination.	PFS will be measured from the date of addition of tildrakizumab to abiraterone to the date of progression as determined by radiological criteria (RECIST v 1.1, PCWG3 bone scan criteria) or unequivocal clinical progression necessitating drug discontinuation (e.g. worsening pain, spinal cord compression, need for other anticancer therapy).	20 months
Secondary	Phase I - To estimate the OS in mCRPC patients receiving the combination of tildrakizumab and abiraterone.	OS will be measured from the date of addition of tildrakizumab to abiraterone to the date of death (whatever cause).	20 months
Secondary	Phase II - To evaluate PFS in mCRPC patients receiving the tildrakizumab and abiraterone combination.	PFS will be measured from the date of addition of tildrakizumab to abiraterone to the date of progression as determined by radiological criteria (RECIST v 1.1, PCWG3 bone scan criteria) or unequivocal clinical progression necessitating drug discontinuation (e.g. worsening pain, spinal cord compression, need for other anticancer therapy).	12 months
Secondary	Phase II - To estimate the biochemical anti-tumour activity of tildrakizumab and abiraterone in mCRPC patients - time to PSA progression.	The time to PSA Progression will be measured from the date of addition of tildrakizumab to abiraterone.	12 months
Secondary	Phase II - To estimate the biochemical anti-tumour activity of tildrakizumab and abiraterone in mCRPC patients - duration of PSA decline by = 50%.	The duration of PSA decline by = 50%, where this is seen in responding patients.	12 months
Secondary	Phase II - To estimate the biochemical anti-tumour activity of tildrakizumab and abiraterone in mCRPC patients - maximum PSA decline.	The maximum PSA decline experienced per patient. This will be measured following the addition of tildrakizumab to abiraterone.	12 months
Secondary	Phase II - To estimate the biochemical anti-tumour activity of tildrakizumab and abiraterone in mCRPC patients - maximum percentage of PSA decline.	The maximum percentage of PSA decline experienced per patient. This will be measured following the addition of tildrakizumab to abiraterone.	12 months
Secondary	Phase II - To determine the pattern of radiologic response to tildrakizumab and abiraterone in mCRPC patients.	Time to radiological progression (RECIST 1.1 & PCWG3 Bone Scan criteria). Radiologic PFS (rPFS).	12 months
Secondary	Phase II - To identify molecular determinants of response and anti-tumour activity of the combination of tildrakizumab and abiraterone in men with mCRPC.	Determine biomarkers of response, including but not limited to PTEN loss, MYC amplification, and intra-tumour MDSC counts, in tumour biopsies from responders and non-responders.	12 months
Secondary	Phase II - To further investigate the PD effects of the tildrakizumab and abiraterone combination in men with mCRPC.	Measure the impact of the downregulation of IL-23 signaling in tumour, also evaluating the downregulation of androgen receptor (AR), AR splice variants, and AR target genes	12 months
Secondary	Phase II - To determine the rate of response based on CTC conversion.	Rate of CTC conversion from = 5/7.5 ml blood to < 5/7.5 ml	12 months
Secondary	Phase II - To estimate the OS in mCRPC patients receiving the combination of tildrakizumab and abiraterone.	OS will be measured from the date of addition of tildrakizumab to abiraterone to the date of death (whatever cause).	12 months
Secondary	Phase II - To further characterise the safety and tolerability profile of the combination of tildrakizumab and abiraterone in men with mCRPC.	Causality and grading severity of each adverse event related to the tildrakizumab and abiraterone combination according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0	12 months